Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 1/20 | 0.41 |
| ▸ | TOP2A | P11388 | 1/20 | 0.41 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.41 |
| ▸ | SNCA | P37840 | 4/20 | 0.41 |
| ▸ | ERN1 | O75460 | 8/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29378214 | 1.00 | TOP1 (0.41) | TOP1TOP2ATOP2BSNCAERN1 | |
| SCHEMBL22485146 | 0.83 | TOP1 (0.43) | TOP1TOP2ATOP2BSNCAERN1 | |
| SCHEMBL22466034 | 0.78 | NPC1 (0.54) | TOP1TOP2ATOP2BSNCAMAPT | |
| SCHEMBL29374896 | 0.78 | NPC1 (0.54) | TOP1TOP2ATOP2BSNCAMAPT | |
| SCHEMBL22466044 | 0.77 | ERN1 (0.50) | TOP1TOP2ATOP2BSNCAERN1 | |
| SCHEMBL29381898 | 0.77 | ERN1 (0.50) | TOP1TOP2ATOP2BSNCAERN1 | |
| SCHEMBL22482236 | 0.77 | SNCA (0.39) | TOP1TOP2ATOP2BSNCAERN1 | |
| SCHEMBL29381620 | 0.76 | SNCA (0.38) | TOP1TOP2ATOP2BSNCAMAPT | |
| SCHEMBL22465929 | 0.76 | SNCA (0.38) | TOP1TOP2ATOP2BSNCAMAPT | |
| SCHEMBL22465864 | 0.75 | SNCA (0.38) | TOP1TOP2ATOP2BSNCAERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114025847-B | Compounds and compositions as modulators of TLR signaling | 神经孔疗法股份有限公司 | 2024-05-24 | — | — | CN | disclosed |
| US-20220298155-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING | NEUROPORE THERAPIES, INC. (US) | 2022-09-22 | — | — | US | disclosed |
| US-11299487-B2 | Compounds and compositions as modulators of TLR signaling | NEUROPORE THERAPIES, INC. (US) | 2022-04-12 | — | — | US | disclosed |
| EP-3946599-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING | Neuropore Therapies, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| CN-114025847-A | Compounds and compositions as modulators of TLR signaling | 神经孔疗法股份有限公司 | 2022-02-08 | — | — | CN | disclosed |
| WO-2020198368-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING | NEUROPORE THERAPIES, INC. (US) | 2020-10-01 | — | — | WO | disclosed |
| WO-2020198368-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING | NEUROPORE THERAPIES, INC. (US) | 2020-10-01 | — | — | WO | disclosed |
| US-20200308163-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING | NEUROPORE THERAPIES, INC. (US) | 2020-10-01 | — | — | US | disclosed |
| US-20200308163-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING | NEUROPORE THERAPIES, INC. (US) | 2020-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220298155-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING | TLR3, TLR6, TLR4 | TOP1 3785/4885TOP2A 2967/4885TOP2B 3443/4885 |
| US-20200308163-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING | TLR3, TLR6, TLR4 | TOP1 3785/4885TOP2A 2967/4885TOP2B 3443/4885 |
| US-11299487-B2 | Compounds and compositions as modulators of TLR signaling | TLR3, TLR6, TLR4 | TOP1 3772/4885TOP2A 2990/4885TOP2B 3418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.